H F Petereit1, A Rubbert-Roth. 1. Department of Neurology, Heilig Geist-Krankenhaus, Köln, Germany. petereit@hgk-koeln.de
Abstract
BACKGROUND: Rituximab, a monoclonal antibody against the B-cell-specific surface protein CD20, is being evaluated for treatment of multiple sclerosis and neuromyelitis optica. Both diseases are restricted to the brain and cerebrospinal fluid (CSF). Whereas the ability of rituximab to deplete B cells in peripheral blood and tissue is well known, little information is available about the ability of rituximab to penetrate the barriers separating brain and CSF from the serum compartment. OBJECTIVE: To measure rituximab levels in serum and CSF of rituximab-treated patients and correlate them with CSF and response markers. METHODS: Fourteen paired serum/CSF samples of patients with autoimmune nervous system disorder were analyzed for up to 43 weeks after rituximab application. RESULTS: Rituximab remains detectable within the CSF after i.v. application for up to 24 weeks. Furthermore, levels of rituximab in CSF correlate significantly with the integrity of the blood CSF barrier.
BACKGROUND:Rituximab, a monoclonal antibody against the B-cell-specific surface protein CD20, is being evaluated for treatment of multiple sclerosis and neuromyelitis optica. Both diseases are restricted to the brain and cerebrospinal fluid (CSF). Whereas the ability of rituximab to deplete B cells in peripheral blood and tissue is well known, little information is available about the ability of rituximab to penetrate the barriers separating brain and CSF from the serum compartment. OBJECTIVE: To measure rituximab levels in serum and CSF of rituximab-treated patients and correlate them with CSF and response markers. METHODS: Fourteen paired serum/CSF samples of patients with autoimmune nervous system disorder were analyzed for up to 43 weeks after rituximab application. RESULTS:Rituximab remains detectable within the CSF after i.v. application for up to 24 weeks. Furthermore, levels of rituximab in CSF correlate significantly with the integrity of the blood CSF barrier.
Authors: Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart Journal: Clin Pharmacokinet Date: 2016-03 Impact factor: 6.447
Authors: Brian L Burnette; Mark A Jentoft; Luis F Porrata; Thomas G Boyce; Thomas E Witzig Journal: J Clin Oncol Date: 2014-01-06 Impact factor: 44.544
Authors: Niyanta N Kumar; Michelle E Pizzo; Geetika Nehra; Brynna Wilken-Resman; Sam Boroumand; Robert G Thorne Journal: Bioconjug Chem Date: 2018-10-24 Impact factor: 4.774
Authors: Daniela Bumbaca Yadav; Janice A Maloney; Kristin R Wildsmith; Reina N Fuji; William J Meilandt; Hilda Solanoy; Yanmei Lu; Kun Peng; Blair Wilson; Pamela Chan; Kapil Gadkar; Andrew Kosky; Marisa Goo; Ann Daugherty; Jessica A Couch; Thomas Keene; Karen Hayes; Lisa Jungbauer Nikolas; Deanna Lane; Robert Switzer; Eric Adams; Ryan J Watts; Kimberly Scearce-Levie; Saileta Prabhu; Lisa Shafer; Deepak R Thakker; Keith Hildebrand; Jasvinder K Atwal Journal: Br J Pharmacol Date: 2017-10-06 Impact factor: 8.739
Authors: Cigall Kadoch; Jing Li; Valerie S Wong; Lingjing Chen; Soonmee Cha; Pamela Munster; Clifford A Lowell; Marc A Shuman; James L Rubenstein Journal: Clin Cancer Res Date: 2013-11-04 Impact factor: 12.531